Alnylam Pharmaceuticals
(NASDAQ:ALNY)
$152.615
-1.775[-1.15%]
Last update: 10:04AM Get Real Time Here
Consensus Rating1
Buy
Highest Price Target1
$395.00
Lowest Price Target1
$143.00
Consensus Price Target1
$194.79

Alnylam Pharmaceuticals Stock (NASDAQ:ALNY), Analyst Ratings, Price Targets, Predictions

Alnylam Pharmaceuticals Inc has a consensus price target of $194.79, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald on March 27, 2024, March 5, 2024, and February 23, 2024. With an average price target of $259.67 between BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 68.19% upside for Alnylam Pharmaceuticals Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Sep 23
1
Oct 23
6
2
Nov 23
2
1
Dec 23
2
2
Jan
2
Feb
7
8
Mar
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BMO Capital
HC Wainwright & Co.
Cantor Fitzgerald
RBC Capital
Wells Fargo

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Alnylam Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/27/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3951.56%BMO Capital
Kostas Biliouris
$234 → $234MaintainsOutperformGet Alert
03/05/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.39155.85%HC Wainwright & Co.
Patrick Trucchio
→ $395ReiteratesBuy → BuyGet Alert
02/23/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.39-2.84%Cantor Fitzgerald
Olivia Brayer
$165 → $150MaintainsNeutralGet Alert
02/21/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3952.21%RBC Capital
Luca Issi
→ $235ReiteratesOutperform → OutperformGet Alert
02/20/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.396.87%Cantor Fitzgerald
Olivia Brayer
→ $165ReiteratesNeutral → NeutralGet Alert
02/20/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3952.21%RBC Capital
Luca Issi
→ $235ReiteratesOutperform → OutperformGet Alert
02/16/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.394.28%Wells Fargo
Tiago Fauth
$171 → $161MaintainsEqual-WeightGet Alert
02/16/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3947.03%Citigroup
David Lebovitz
$237 → $227MaintainsBuyGet Alert
02/16/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3952.21%RBC Capital
Luca Issi
→ $235ReiteratesOutperform → OutperformGet Alert
02/16/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3945.73%Chardan Capital
Keay Nakae
$250 → $225MaintainsBuyGet Alert
02/16/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3912.05%Goldman Sachs
Salveen Richter
$230 → $173DowngradeBuy → NeutralGet Alert
02/15/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3929.54%Needham
Joseph Stringer
→ $200ReiteratesBuy → BuyGet Alert
02/15/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.396.87%Cantor Fitzgerald
Olivia Brayer
→ $165ReiteratesNeutral → NeutralGet Alert
02/15/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.39Wolfe Research
Andy Chen
Initiates → Peer PerformGet Alert
02/14/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3952.21%RBC Capital
Luca Issi
→ $235ReiteratesOutperform → OutperformGet Alert
02/13/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3914%Morgan Stanley
Michael Ulz
$184 → $176MaintainsEqual-WeightGet Alert
02/12/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.396.87%Cantor Fitzgerald
Olivia Brayer
→ $165ReiteratesNeutral → NeutralGet Alert
02/01/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.3910.11%JP Morgan
Jessica Fung
$150 → $170MaintainsNeutralGet Alert
01/22/2024ALNYBuy Now
Alnylam Pharmaceuticals
$154.396.87%Cantor Fitzgerald
Olivia Brayer
→ $165ReiteratesNeutral → NeutralGet Alert

FAQ

Q

What is the target price for Alnylam Pharmaceuticals (ALNY)?

A

The latest price target for Alnylam Pharmaceuticals (NASDAQ: ALNY) was reported by BMO Capital on March 27, 2024. The analyst firm set a price target for $234.00 expecting ALNY to rise to within 12 months (a possible 53.33% upside). 65 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?

A

The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ: ALNY) was provided by BMO Capital, and Alnylam Pharmaceuticals maintained their outperform rating.

Q

When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?

A

The last upgrade for Alnylam Pharmaceuticals Inc happened on May 5, 2023 when BMO Capital raised their price target to $250. BMO Capital previously had a market perform for Alnylam Pharmaceuticals Inc.

Q

When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?

A

The last downgrade for Alnylam Pharmaceuticals Inc happened on February 16, 2024 when Goldman Sachs changed their price target from $230 to $173 for Alnylam Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

Q

Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?

A

While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $234.00 to $234.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $152.62, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch